20/20 Biolabs gets Nasdaq notice over $2.5 million stockholders’ equity shortfall
AIDX•Stockholders’ equity shortfall and turnaround plan
Nasdaq also cited stockholders’ equity below the $2.5 million minimum, with equity reported at $1,620,700 in the June 30, 2026 quarter.
A turnaround plan is due within 45 days; failure to fix equity by Jan. 13, 2027 could block extra time on the bid-price cure.
Nasdaq notices over bid-price and equity deficiencies
20/20 Biolabs received Nasdaq notices for failing continued listing standards, raising delisting risk if deficiencies are not cured.
Nasdaq flagged a sub-$1 bid price over June 3–July 16, 2026; compliance deadline set for Jan. 13, 2027.
The stock must close at $1 or higher for 10 consecutive sessions to regain compliance within the initial 180-day window.
